- Patient’s characteristics, treatment plan, and outcome.
| Case | Age (days)/gender | Primary site | Metastatic lesion | Histology | N-MYC | Clinical Philadelphia* Score | Chemotherapy # cycles | Follow up (month) | Outcome | |
|---|---|---|---|---|---|---|---|---|---|---|
| Initial prsentation | At progression | |||||||||
| 1 | 52/M | Right supra-renal | Hepatic lesions | Poorly differentiated | NA | 0 | 1 | 8 | 84 | Alive |
| 2 | 98/F | Bilateral supra-renal | Hepatic lesions | FH | NA | 0 | 0 | 0 | 81 | Alive |
| 3 | 82/F | Retroperi-toneal | Hepatic lesions† | Poorly differentiated | NA | 0 | 1 | 4 | 45 | Alive |
| 4 | 104/F | Right supra-renal | Hepatic lesions | FH | NA | 2 | 2 | 8 | 41 | Alive |
| 5 | 114/M | Retroperitoneal | Hepatic lesions | FH | NA | 0 | 1 | 8 | 33 | Alive |
| 6 | 65/F | Left supra-renal | Hepatic lesions | FH | NA | 0 | 1 | 4 | 31 | Alive |
↵* Adapted from “Hepatomegaly in neuroblastoma stage 4S: criteria for treatment” by Hsu et al.7 0=asymptomatic, 1=mild/moderate, 2=severe, organ function compromise, F: female, M: male, NA: not amplified, FH: favorable histology (children younger than 18 months with a low or intermediate mitosis-karyorrhexis index; A differentiating or partially differentiating tumor and not amplified [N-MYC]).
↵† Hepatic lesion biopsy after 1st cycle of chemotherapy.